Tag: PPE

Department of Health and Social Care 2020–21

Annual report and accounts

Source: House of Commons Committee of Public Accounts

This report finds that the Department for Health and Social Care lost 75 per cent of the £12 billion it spent on personal protective equipment (PPE) in the first year of the pandemic to inflated prices and kit that did not meet requirements – including £4 billion of PPE that will not be used in the NHS and needs to be disposed of. The report also voices concerns about the risk of further payouts as NHS commissioning is restructured under upcoming reforms.

Royal College of Nursing

Independent Review

Source: The King’s Fund Health Management and Policy Alert

This report of an independent review finds that the government’s Covid-19 infection control guidelines, which are used across the UK, are in need of updating. It calls for all NHS staff to be given a higher level of personal protective equipment as a precautionary measure pending the outcome of a review. 

For more information click here.

Covid 19

Current awareness updates

Ethnic inequalities in Covid-19 mortality: a consequence of persistent racism Runnymede Trust

(This briefing (published in collaboration with the Centre of Dynamics of Ethnicity) discusses the reasons for ethnic minority people experiencing a much higher risk of Covid-19-related death. Ethnic inequalities in relation to Covid-19 mirror longstanding ethnic inequalities in health. A large body of evidence has shown that these inequalities are driven by social and economic inequalities, many of which are the result of racial discrimination.)

PPE portal: how to order COVID-19 personal protective equipment (PPE) – Public Health England; Updated 26th January 2021

(Eligible health and social care providers can order PPE through the portal to meet the increased need that has arisen as a result of the COVID-19 pandemic)

COVID-19 variants: genomically confirmed case numbers Public Health England; Updated 28th January 2021

(Genomically confirmed case numbers for SARS-CoV-2 variants of concern and variants under investigation.)

Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update European Centre for Disease Prevention and Control

(This risk assessment presents the latest available information on the recent emergence of three variants of concern, VOC 202012/01 identified in the United Kingdom (UK), 501Y.V2 identified in South Africa, and P.1 identified in Brazil and Japan)

COVID-19 in children and the role of school settings in transmission – first update European Centre for Disease Prevention and Control

(The aim of this document is to provide an update on the knowledge surrounding the role of children in the transmission of SARS-CoV-2 and the role of schools in the COVID-19 pandemic, based on the experience in the EU from August–December, 2020. This document also addresses transmission to and from staff in school settings, school-related mitigation measures including risk communication, testing, contact tracing and the efficacy of partial and full school closures. This document draws upon and updates evidence presented in the previous report from ECDC on this topic, which was published on August 6, 2020 [4]. This report does not consider educational settings related to young adults or adults, such as universities or vocational schools or any school with overnight stays, such as boarding schools. This report does not consider the epidemiology of COVID-19 in relation to new variants of SARS-CoV-2, for which robust evidence on the potential impact in school settings is not yet available, such as one recently observed in the United Kingdom [2].)

COVID-19 rapid evidence summary: Sarilumab for COVID-19.
National Institute for Health and Care Excellence (NICE); 2021.

(Preliminary evidence from the REMAP‑CAP study has suggested that sarilumab is beneficial in adults with severe COVID‑19 who are critically ill and receiving respiratory or cardiovascular organ support in an intensive care setting. Sarilumab was given within about 24 hours of starting organ support.)


COVID-19 rapid evidence summary: Tocilizumab for COVID-19.
National Institute for Health and Care Excellence (NICE); 2021.

(Unpublished preliminary evidence from the REMAP‑CAP study has suggested that tocilizumab is beneficial in adults with severe COVID‑19 who are critically ill and receiving respiratory or cardiovascular organ support in an intensive care setting (all randomised within 24 hours of starting organ support).)

Perspectives from the front line: The disproportionate impact of COVID-19 on BME communities.
NHS Confederation BME Leadership Network; 2020.

(A report into the disproportionate impact of coronavirus on BAME communities based on interviews with BME NHS leaders, clinicians, community organisations and service users, as well as a survey of more than 100 members of the BME Leadership Network. Overwhelmingly, participants point to long-standing inequalities and institutional racism as root causes.)